NYSE:MTNB | Free Cash Flow | Matinas BioPharma Holdings, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2013-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$1.6M
2025-12-31-$1.51M
2025-03-31-$2.01M
2024-12-31-$3.51M
2024-03-31-$5.77M
2023-12-31-$4.58M$0.00-$4.58M
2023-03-31-$4.09M
2022-12-31-$4.3M$42,000.00-$4.34M
2022-03-31-$4.76M$545,000.00-$5.3M
2021-12-31-$3.96M$35,812.00-$3.99M
2021-09-30$224,000.00
2021-03-31-$4.65M
2020-12-31-$4.31M$0.00-$4.31M
2020-09-30$0.00
2020-03-31-$4.66M$5,749.00-$4.67M
2019-12-31-$4.9M$0.00-$4.9M
2019-03-31-$3.02M$14,246.00-$3.04M
2018-12-31-$2.62M$0.00-$2.62M
2018-03-31-$2.81M$101,916.00-$2.91M
2017-12-31-$1.92M$118,294.00-$2.03M
2017-03-31-$3.03M
2016-12-31-$2.12M$0.00-$2.12M
2016-03-31-$1.54M$0.00-$1.54M
2015-12-31-$1.12M$22,932.00-$1.14M
2015-03-31-$2.32M$4,845.00-$2.33M
2014-12-31-$2.42M$1.00-$2.42M
2014-03-31-$2.09M$193,277.00-$2.28M
2013-12-31-$1.67M$65,890.00-$1.73M
2013-03-31-$150,123.00$0.00-$150,123.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$7.01M
2024-12-31-$15.89M
2023-12-31-$15.28M$218,000.00-$15.5M
2022-12-31-$19.16M$892,000.00-$20.05M
2021-12-31-$15.22M$260,000.00-$15.48M
2020-12-31-$17.37M$5,749.00-$17.37M
2019-12-31-$14.09M$405,604.00-$14.5M
2018-12-31-$10.32M$535,916.00-$10.86M
2017-12-31-$11.46M$942,180.00-$12.4M
2016-12-31-$6.12M$0.00-$6.12M
2015-12-31-$7.81M$76,179.00-$7.89M
2014-12-31-$7.96M$288,519.00-$8.25M
2013-12-31-$2.99M$94,188.00-$3.08M